W81XWH-21-NFRP-CTCA: DOD Neurofibromatosis, Clinical Trial Consortium Award
Closed
This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2021.
Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make one award worth $25.0 million in total. Applications closed on October 29, 2021.
From the official notice on Grants.gov, last changed August 20, 2021. Checked November 7, 2026.
- Total funding$25.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeOther
Key dates
| Posted | August 20, 2021 |
|---|---|
| Deadline | October 29, 2021 |
| Archived by Grants.gov | November 28, 2021 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Most of the program's money (59% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The NFRP Clinical Trial Consortium Award mechanism was first offered in FY06, and subsequently in FY11 and FY16, with awards being made as grants or cooperative agreements. This FY21 research announcement is being offered through a different type of award mechanism, a Research Other Transaction Award (rOTA) under the authority of 10 USC 2371. The FY21 NFRP Clinical Trial Consortium Award is intended to support a major goal/product-driven consortium of exceptional institutions and investigators that will accelerate the clinical translation of basic NF research and ultimately decrease the impact of the disease. The objectives of the rOTA are the conception, design, development, and conduct of collaborative Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis. Research Other Transaction Agreement The principal purpose of a rOTA is to carry out non-duplicative basic, applied, and advanced research projects rather than the acquisition of property or services for the direct benefit or use of the government. The anticipated deliverables to the government under a rOTA are reports on research rather than prototypes. Additionally, a rOTA has several features that differ from those of the previous award types offered for the NFRP Clinical Trial Consortium. The rOTA requires resource sharing, with government funds not to exceed the total amount provided by other parties to the maximum extent practicable. Offerors will be required to demonstrate how resources (e.g., cash and non-cash) will be made available for this project. Please also note that the government’s funds will not be front-loaded, with certain matches being required before additional government funds are made available. The rOTA is intended to promote the use of best business practices and to foster relationships among performers from different sectors. In addition, as a matter of DOD policy, rOTAs may only be awarded when one or more for-profit firms are to be involved either in the: (1) performance of the research project(s) or (2) commercial application of the research results. A consortium should either include, collaborate with, or involve one or more for-profit firms in addition to state or local government agencies, institutions of higher education, or other nonprofit organizations.
Who has won Military Medical Research and Development grants before
From fiscal 2021 to 2025, Military Medical Research and Development (12.420) awarded $6.9 billion across 5,470 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Maryland | 81 | $546 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 139 | $166 million |
| The Johns Hopkins University | Maryland | 157 | $153 million |
| The Regents of the University of California, San Francisco | California | 113 | $147 million |
| Duke University | North Carolina | 86 | $123 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is W81XWH-21-NFRP-CTCA still open?
No. It closed on October 29, 2021. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).
Who can apply for DOD Neurofibromatosis, Clinical Trial Consortium Award?
Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.
What is the deadline for DOD Neurofibromatosis, Clinical Trial Consortium Award?
Closed October 29, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $25.0 million in total for one award.
Who has won Military Medical Research and Development grants before?
The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.